Frontiers in Shigella Vaccine Development.

In recent years, there has been a resurgence of interest in the development of vaccines against I Shigella i driven by the growing awareness of the impact of this pathogen on global health. This is now being assessed in a Phase 3 study in China and is the most advanced I Shigella i vaccine and, as far as we are aware, the only multivalent I Shigella i vaccine to be assessed in a Phase 3 study to date [[17]]. Finally, we provide, in a separate article, a description of the I Shigella i vaccine pipeline putting the various current candidates covered in this Special Issue in context with vaccines whose development has been halted for one or other reason [[31]]. As a result, the development of many I Shigella i vaccines has been described piecemeal over several years and in multiple papers, none providing the full story of the vaccine they relate to. [Extracted from the article]